Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18977228 | Ribociclib Tablet | December 2024 | June 2025 | Allow | 7 | 3 | 0 | Yes | No |
| 18953665 | TAMPER RESISTANT DOSAGE FORMS | November 2024 | August 2025 | Abandon | 9 | 2 | 0 | No | No |
| 18829557 | NOVEL LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | September 2024 | April 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18819147 | DELAYED RELEASE SOFTGEL CAPSULES IN HIGHER PH ENVIRONMENT | August 2024 | December 2025 | Allow | 16 | 4 | 0 | No | No |
| 18786785 | METHOD FOR HYPERTHERMIALLY TREATING A CANCER | July 2024 | October 2024 | Allow | 2 | 1 | 0 | No | No |
| 18745602 | SYSTEMS AND METHODS FOR BLENDING SOLID-SHELL COSMETIC INGREDIENT CAPSULES AND BLENDABLE COSMETIC INGREDIENT CAPSULES | June 2024 | July 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18632164 | PAINLESS NGF FOR FRACTURE REPAIR | April 2024 | May 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18603884 | TAMPER RESISTANT DOSAGE FORMS | March 2024 | July 2024 | Allow | 4 | 3 | 0 | No | No |
| 18599893 | HIGH STEROL-CONTAINING LIPID NANOPARTICLES | March 2024 | April 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18583383 | OCULAR HYDROGEL TYROSINE KINASE INHIBITOR IMPLANTS | February 2024 | February 2026 | Abandon | 24 | 3 | 0 | No | No |
| 18681556 | PREPARATION OF COMPOSITE GELS, POLYMER SCAFFOLDS, AGGREGATES AND FILMS COMPRISING SOLUBLE CROSS-LINKED CHITOSAN & USES THEREOF | February 2024 | May 2025 | Allow | 15 | 2 | 1 | Yes | No |
| 18431035 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | February 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18399841 | METHOD FOR MICROORGANISM GROWTH INHIBITION | December 2023 | February 2026 | Allow | 25 | 1 | 0 | No | No |
| 18395521 | IMPLANTABLE POLYMER FOR BONE AND VASCULAR LESIONS | December 2023 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18531424 | HETEROCYCLIC COMPOUNDS AND THEIR USES | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18512499 | CANCER TREATMENT METHOD FOR MAGNETIC HYPOTHERMIA CANCER TREATMENT | November 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18384378 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK INHIBITOR AND DEVICES | October 2023 | January 2026 | Abandon | 26 | 4 | 0 | No | No |
| 18490896 | CANNABINOID CHEWING GUM WITH SUGAR ALCOHOLS | October 2023 | January 2026 | Allow | 27 | 6 | 0 | Yes | No |
| 18475755 | TAMPER RESISTANT DOSAGE FORMS | September 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18372560 | Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional Supplement | September 2023 | December 2024 | Allow | 15 | 2 | 0 | No | No |
| 18464844 | MICROGELS FOR THE DELIVERY OF COSMETIC ACTIVE ORGANIC SUBSTANCES | September 2023 | October 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18459805 | POLYCAPROLACTONE-BASED FIBERS AND IMPLANTS INCLUDING SAME | September 2023 | November 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18450842 | METHOD FOR TREATING BREAST CANCER | August 2023 | November 2023 | Allow | 3 | 1 | 0 | No | No |
| 18275832 | HYDROGEL STRUCTURE | August 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18337570 | COSMETIC COMPOSITIONS CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO A KERATINOUS MATERIAL | June 2023 | August 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18205786 | TAMPER RESISTANT DOSAGE FORMS | June 2023 | December 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18204233 | Polyphosphate-Functionalized Inorganic Nanoparticles as Hemostatic Compositions and Methods of Use | May 2023 | November 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 18037901 | HERBICIDAL MALONAMIDES | May 2023 | March 2026 | Allow | 34 | 1 | 1 | No | No |
| 18143927 | TAMPER RESISTANT DOSAGE FORMS | May 2023 | September 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18307887 | Sutures with Expanded Antibacterial Properties | April 2023 | March 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18248615 | COMPOSITIONS AND METHODS PROMOTING GROWTH OF PERIPHERAL NERVOUS TISSUE | April 2023 | January 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18298623 | TRANSDERMAL DELIVERY SYSTEM WITH A MICROPOROUS MEMBRANE HAVING SOLVENT-FILLEDPORES | April 2023 | May 2025 | Abandon | 25 | 3 | 0 | No | No |
| 18130142 | METHODS OF PREPARING MULTIPHASE STATIN AND OMEGA-3 FATTY ACID SOFT CAPSULE FORMULATIONS | April 2023 | October 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 18187904 | HIGH STEROL-CONTAINING LIPID NANOPARTICLES | March 2023 | December 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18184816 | IMPLANTABLE MEDICAL DEVICE WITH THERMOPLASTIC COMPOSITE BODY AND METHOD FOR FORMING THERMOPLASTIC COMPOSITE BODY | March 2023 | December 2023 | Allow | 9 | 2 | 0 | No | No |
| 18117315 | HYDRATION COMPOSITIONS | March 2023 | November 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 18115854 | HEARTWORM MEDICAMENT | March 2023 | August 2023 | Allow | 6 | 1 | 0 | No | No |
| 18174674 | DRY POWDER FORMULATIONS FOR INHALATION | February 2023 | July 2024 | Allow | 16 | 2 | 0 | No | No |
| 18040597 | ADVANCED DRESSING CONTAINING A POLYCAPROLACTONE POROUS MEMBRANE | February 2023 | February 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18099953 | FORMULATIONS WITH COLLOIDAL SILVER | January 2023 | November 2024 | Allow | 22 | 2 | 0 | No | No |
| 18156151 | MEANS AND METHODS OF STERILIZATION OF BIOFUNCTIONAL COMPOSITIONS | January 2023 | October 2025 | Abandon | 33 | 1 | 0 | No | No |
| 18152965 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING A SILICONE POLYMER | January 2023 | July 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18095329 | SELF-LUBRICATING MEDICAL ARTICLES | January 2023 | January 2025 | Allow | 24 | 4 | 0 | No | No |
| 18151144 | Portable Scent Diffuser Device and Method of Use Thereof | January 2023 | September 2025 | Allow | 32 | 0 | 0 | No | No |
| 18014197 | STABLE SOLID FORMULATION OF AZILSARTAN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | January 2023 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18148724 | Oral Care Compositions | December 2022 | March 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18013815 | NANOPARTICLE CONTAINING HYDROPHOBIC SUBSTANCE AND MANUFACTURING PROCESS AND USE THEREOF | December 2022 | November 2025 | Allow | 35 | 1 | 0 | No | No |
| 18003507 | Nanoparticle with a Buffer Layer | December 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 18146736 | Core-Shell Microcapsule with a Polyamine-Based Thermosetting Shell | December 2022 | May 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18068791 | DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME | December 2022 | February 2026 | Allow | 38 | 1 | 1 | Yes | No |
| 18083774 | SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUND | December 2022 | November 2024 | Abandon | 23 | 2 | 0 | No | No |
| 18072772 | TREATMENT OF IMMUNE DISEASES BY ADMINISTRATION OF ANTIGEN-SPECIFIC FORMULATIONS | December 2022 | November 2023 | Allow | 11 | 1 | 0 | No | No |
| 17928271 | COMPOSITIONS FOR THE TREATMENT OF A RESPIRATORY CONDITION | November 2022 | February 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17999925 | PROCESS FOR MANUFACTURING A COMPRESSED PRODUCT | November 2022 | October 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17985757 | SYSTEMS AND METHODS FOR BLENDING SOLID-SHELL COSMETIC INGREDIENT CAPSULES AND BLENDABLE COSMETIC INGREDIENT CAPSULES | November 2022 | February 2024 | Allow | 15 | 1 | 0 | No | No |
| 17977902 | GELLING MULTIPARTICULATES | October 2022 | March 2024 | Allow | 17 | 1 | 0 | No | No |
| 17971025 | COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS | October 2022 | April 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 17917455 | Safe Use of Bile Acids and Their Salts as Enhancers for Nasal Delivery of Pharmaceuticals | October 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17915050 | COMPOSITION AND PRODUCT THEREOF | September 2022 | March 2026 | Allow | 41 | 4 | 0 | Yes | No |
| 17954279 | Compositions for Inhibition of Insect Sensing | September 2022 | March 2025 | Abandon | 29 | 0 | 1 | No | No |
| 17934737 | COSMETIC COMPOSITIONS CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO A KERATINOUS MATERIAL | September 2022 | March 2023 | Allow | 5 | 1 | 0 | No | No |
| 17912349 | PROCESS FOR MANUFACTURING AN INJECTION AGENT AND INJECTION AGENT OBTAINABLE BY THIS PROCESS | September 2022 | October 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17908860 | STRUCTURE REINFORCING MATERIAL | September 2022 | September 2025 | Allow | 37 | 1 | 0 | No | No |
| 17802984 | PROTEIN PRODUCT CAPABLE OF IMMOBILIZING TARGET AND BEING CLEARED AS REQUIRED | August 2022 | February 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 17892553 | TAMPER RESISTANT DOSAGE FORMS | August 2022 | December 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17801231 | METHOD OF MANUFACTURING ORAL DOSAGE FORMS FOR EXTENDED DRUG RELEASE | August 2022 | December 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17798951 | NANOPARTICLE SOLUTIONS, KITS, DEVICES AND METHODS OF USE THEREOF | August 2022 | December 2025 | Allow | 40 | 1 | 1 | No | No |
| 17818687 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | August 2022 | September 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17762078 | PROBIOTIC MICROCAPSULE AND PREPARATION METHOD THEREOF | August 2022 | September 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17880175 | OCULAR HYDROGEL TYROSINE KINASE INHIBITOR IMPLANTS | August 2022 | August 2024 | Abandon | 24 | 1 | 0 | No | Yes |
| 17877542 | PREPARATION CONTAINING TETRACYCLIC COMPOUND AT HIGH DOSE | July 2022 | January 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17873968 | METHODS OF TREATING PATIENTS AT RISK FOR RENAL INJURY AND RENAL FAILURE | July 2022 | December 2023 | Allow | 17 | 1 | 0 | No | No |
| 17759259 | DENTAL PREPARATION COMPRISING FIBERS BASED ON HYALURONIC ACID WITH REGULATED BIODEGRADABILITY | July 2022 | December 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17856682 | COMPOSITIONS AND RESULTING HARD CAPSULES COMPRISING HYDROPHILIC COLORING FOODSTUFF CONCENTRATES | July 2022 | December 2023 | Allow | 18 | 2 | 0 | No | No |
| 17810274 | SHAPE MEMORY ADHESIVES FOR APPAREL PRODUCTS | June 2022 | July 2023 | Allow | 12 | 2 | 1 | Yes | No |
| 17757791 | SHELF-STABLE HYPOCHLOROUS ACID | June 2022 | October 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17806033 | HETEROCYCLIC COMPOUNDS AND THEIR USES | June 2022 | September 2023 | Allow | 15 | 1 | 0 | No | No |
| 17805956 | Ribociclib Tablet | June 2022 | December 2023 | Allow | 18 | 1 | 0 | No | No |
| 17835739 | NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING | June 2022 | June 2025 | Allow | 37 | 3 | 1 | Yes | No |
| 17827504 | NATURAL COMPOSITION FOR USE IN GYNAECOLOGY | May 2022 | October 2023 | Allow | 17 | 2 | 0 | No | No |
| 17826803 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | May 2022 | October 2025 | Allow | 41 | 1 | 1 | No | No |
| 17824425 | TOPICAL COMPOSITION AND METHOD OF USE | May 2022 | August 2024 | Allow | 27 | 1 | 1 | No | No |
| 17752813 | Scaffold for Regenerative Organization of Prosthetic Organ Tissue and Method | May 2022 | March 2024 | Abandon | 22 | 2 | 1 | Yes | No |
| 17778321 | ANTI-CANCER COMPOSITIONS AND METHODS | May 2022 | January 2026 | Abandon | 44 | 2 | 1 | No | No |
| 17747006 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | May 2022 | December 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17777715 | HAIR CARE COMPOSITION | May 2022 | November 2025 | Allow | 42 | 2 | 1 | No | No |
| 17773799 | HYDROPHILIC MEDICAL PRODUCTS AND HYDRATION MEDIUMS FOR HYDRATING THE SAME | May 2022 | October 2025 | Allow | 41 | 1 | 1 | No | No |
| 17771784 | METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | April 2022 | August 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17721183 | METHOD OF TREATING EPILEPSY | April 2022 | June 2024 | Allow | 26 | 4 | 0 | Yes | No |
| 17766976 | Oral Care Compositions and Methods of Use | April 2022 | December 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17712618 | Method and Apparatus for Treating Bone Fractures, and/or for Fortifying and/or Augmenting Bone, Including the Provision and Use of Composite Implants | April 2022 | October 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17699919 | HEMOSTATIC PASTE AND METHODS OF MAKING THEREOF | March 2022 | March 2023 | Allow | 12 | 2 | 0 | No | No |
| 17762029 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, AN EFFECT PIGMENT AND A POST-TREATMENT AGENT | March 2022 | August 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17691299 | Capsule to support the body's defense against microplastics | March 2022 | January 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17641056 | ONIUM SALT OF NITROGEN-CONTAINING HETEROARYL COMPOUND AND PEST CONTROL AGENT | March 2022 | June 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17686827 | Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional Supplement | March 2022 | September 2023 | Allow | 18 | 4 | 0 | Yes | No |
| 17640567 | MICROCAPSULE AND HAIR CARE COMPOSITION | March 2022 | August 2025 | Allow | 42 | 2 | 0 | No | No |
| 17639932 | AQUEOUS CONDITIONER FORMULATION FOR THERMALLY STYLED HAIR | March 2022 | March 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17680646 | Polyurethane Based Medical Articles | February 2022 | July 2024 | Allow | 29 | 2 | 1 | No | No |
| 17631775 | METHOD FOR TREATING KERATIN MATERIAL, COMPRISING THE USE OF AN ORGANIC C1-C6-ALKOXY-SILANE AND AN AMINO ACID AND/OR AN AMINO ACID DERIVATIVE | January 2022 | March 2025 | Abandon | 38 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FUBARA, BLESSING M.
With a 42.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FUBARA, BLESSING M works in Art Unit 1613 and has examined 1,135 patent applications in our dataset. With an allowance rate of 66.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 28 months.
Examiner FUBARA, BLESSING M's allowance rate of 66.3% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by FUBARA, BLESSING M receive 2.27 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by FUBARA, BLESSING M is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +36.4% benefit to allowance rate for applications examined by FUBARA, BLESSING M. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.4% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 38.0% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 90.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 67% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 74.2% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 53.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 62.5% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.6% of allowed cases (in the 72% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.5% of allowed cases (in the 75% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.